NDC 43598-262-11 - Fulvestrant
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 43598-262
- Requested NDC
- 43598-262-11
- Package NDCs from labels
- 43598-262-11, 43598-262-02, 43598-262-23
- Manufacturer
- Dr.Reddy's Laboratories Inc | Dr.Reddy's Laboratories Limited-FTO-9
- Effective date
- 2025-11-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Fulvestrant - Dr.Reddy's Laboratories Inc | Dr.Reddy's Laboratories Limited-FTO-9 | Dr.Reddy's Laboratories Inc | Dr.Reddy's Laboratories Limited-FTO-9 | 2025-11-01 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 43598-262-02 | Fulvestrant | 2 in 1 CARTON | INJECTION, SOLUTION | 2 | 19 | |
| 43598-262-11 | Fulvestrant | 5 mL in 1 SYRINGE, GLASS | INJECTION, SOLUTION | 5 | 19 | |
| 43598-262-23 | Fulvestrant | 2 in 1 CARTON | INJECTION, SOLUTION | 2 | 19 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 43598-262-02 | ML - Milliliter | 43598-262 | ffea5f6c-7731-4740-a3f9-edad8d056f49 | 1 | 2020-09-14 |
| 43598-262-11 | ML - Milliliter | 43598-262 | 03ff9a88-c9c3-4495-be64-9a6c0bc83841 | 1 | 2020-09-14 |
| 43598-262-23 | ML - Milliliter | 43598-262 | a0670a5a-4694-44ec-9686-8ad954149217 | 1 | 2024-10-04 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CLIGAVYX | FULVESTRANT | Avyxa Pharma, LLC | e20d8ca3-8837-4003-8b01-1ebec342062a | 2026-06-24 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| fulvestrant | FULVESTRANT | Sagent Pharmaceuticals | d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8 | 2026-03-05 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | GLENMARK PHARMACEUTICALS INC., USA | 99cf8b69-4c23-4886-80e9-b23e348b5bd7 | 2026-02-27 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 46086fe7-190d-4963-97bc-1fe22d36e6d2 | 2025-12-23 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Alembic Pharmaceuticals Inc. | b02915fe-6c44-48c1-aaeb-997ddc59a595 | 2025-08-18 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | BluePoint Laboratories. | 57352662-d2fa-4dce-828f-4c51e46e0b4d | 2025-07-25 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Eugia US LLC | 80b6dfe6-449d-4e2f-af90-bfbf9b04163b | 2025-07-03 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | BluePoint Laboratories | bc7b4eac-3b63-53d2-e053-2995a90ad5e7 | 2025-06-24 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Amneal Pharmaceuticals LLC | f36f19ad-f044-4dba-80b6-d074ddffcd86 | 2025-05-30 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Amneal Pharmaceuticals LLC | a51aa693-b433-4b2d-a71b-9ba029b10ce3 | 2025-04-30 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| FULVESTRANT | FULVESTRANT | Accord Healthcare Inc. | b471eb51-488e-5312-e053-2a95a90a8116 | 2025-03-10 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Hikma Pharmaceuticals USA Inc. | 306c283b-9abe-4985-856b-1957f1f3af8b | 2025-02-10 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Athenex Pharmaceutical Division, LLC. | 8ed06e0e-c17b-4c71-8d03-888bcde4a638 | 2025-01-28 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| FULVESTRANT | FULVESTRANT | Zydus Pharmaceuticals USA Inc. | 994edf79-20a5-4e3a-bb35-c4fe3e65acba | 2024-08-20 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Dr.Reddy's Laboratories Inc | 2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682 | 2024-07-31 | Warnings, Adverse reactions | ANDA209246 43598-262-23 43598-262-11 43598-262-02 43598-262 43598026211 727762 67af235f-7f8b-da5b-5eb6-91d0b20b2a9e 2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Meitheal Pharmaceuticals Inc | 015fafb6-23f7-4566-9c23-386eee7b035d | 2024-06-17 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Avenacy, Inc. | f44cffcc-8f5e-4a4c-a36e-ab946ce86266 | 2024-02-28 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Fresenius Kabi USA, LLC | fabe9bd8-ac23-4df1-a89a-223d5cd38914 | 2024-01-31 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Sandoz Inc | 7a03f714-b109-4256-80a6-78c82127d624 | 2022-09-21 | Warnings, Adverse reactions | 727762 22X328QOC4 |
| Fulvestrant | FULVESTRANT | Sandoz Inc | 141f439e-078c-4a59-acff-ebf7685f55b8 | 2022-09-13 | Warnings, Adverse reactions | 727762 22X328QOC4 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.